Has CAR-T lost its luster? Why is colorectal cancer on the rise? And did the FDA forever change in 2016?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dig into the news out of this week’s big hematology conference, where novel treatments for blood cancer threatened the future of genetically engineered CAR-T therapies. Then, former Sarepta Therapeutics CEO Chris Garabedian joins us to talk about the company’s regulatory legacy and what he’s been up to since leaving it. Finally, we talk to Manju George, a patient activist working to spread the word about the alarming increase of colorectal cancer among young people.
For more on what we cover, here’s the news in hematology; here’s more on Garabedian’s work; and here’s some background on colorectal cancer patient activism.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email email@example.com.
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at firstname.lastname@example.org.